WP 1066

Drug Profile

WP 1066

Alternative Names: WP1066

Latest Information Update: 02 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Mayo Clinic; Moleculin Biotech; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Pyridines; Small molecules
  • Mechanism of Action Immunostimulants; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Brain metastases; Glioblastoma
  • Preclinical Acute myeloid leukaemia; Eye neoplasms; Glioma; Pancreatic cancer

Most Recent Events

  • 31 Jul 2018 Moleculin Biotech initiates enrolment in a physician-sponsored phase I trial for Glioma (Recurrent) and Brain metastases (from melanoma) in USA (NCT01904123)
  • 08 Jun 2018 Chemical structure information added
  • 15 May 2018 MD Anderson Cancer Center, National Institutes of Health and National Cancer Institute plans a phase I trial for Glioma (Recurrent) and Brain metastases (from melanoma) in USA (PO) in second half of 2018 (NCT01904123)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top